Effect of pentoxifylline on microalbuminuria in diabetic patients: a randomized controlled trial.

Shahrzad Shahidi,Mojtaba Akbari,Marziyeh Hoseinbalam,Bijan Iraj

doi:10.1155/2015/259592

Abstract

Background. Pentoxifylline is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties. Human studies have proved its antiproteinuric effect in patients with glomerular diseases, but this study was designed to assess the effects of add-on pentoxifylline to available treatment on reduction of microalbuminuria in diabetic patients without glomerular diseases. Methods. In a double-blind placebo-controlled, randomized study we evaluated the influence of pentoxifylline on microalbuminuria in type 2 diabetic patients. 40 diabetic patients with estimated glomerular filtration rate (eGFR) of more than 60 mL/min/1.73 m2 in eight weeks and microalbuminuria were randomized to two groups which will receive pentoxifylline 1200 mg/day or placebo added to regular medications for 6 months. albuminuria; eGFR was evaluated at three- and six-month follow-up period. Results. Baseline characteristics were similar between the two groups. At six months, the mean estimated GFR and albuminuria were not different between two groups at 3- and 6-month follow-up. Trend of albumin to creatinine ratio, systolic and diastolic blood pressure, and eGFR in both groups were decreased, but no significant differences were noted between two groups (P value > 0.05). Conclusion. Pentoxifylline has not a significant additive antimicroalbuminuric effect compared with placebo in patients with type 2 diabetes with early stage of kidney disease; however, further clinical investigations are necessary to be done.

Highlights

Diabetes is among the most common and major diseases in the world and recently in most countries the number of patients with diabetes has strikingly increased
Microalbuminuria indicates a possibility of ongoing renal involvement due to diabetic nephropathy which results in end stage renal disease [13]
In type 2 diabetes, microalbuminuria or overt proteinuria may be present by the time of diagnosis and the latter is often accompanied by hypertension in these patients; conditions such as congestive heart failure, hypertension, and infections can lead to microalbuminuria in diabetic patients [2, 14]

Summary

Introduction

Diabetes is among the most common and major diseases in the world and recently in most countries the number of patients with diabetes has strikingly increased. Microalbuminuria indicates a possibility of ongoing renal involvement due to diabetic nephropathy which results in end stage renal disease [13]. In a double-blind placebo-controlled, randomized study we evaluated the influence of pentoxifylline on microalbuminuria in type 2 diabetic patients. 40 diabetic patients with estimated glomerular filtration rate (eGFR) of more than 60 mL/min/1.73 m2 in eight weeks and microalbuminuria were randomized to two groups which will receive pentoxifylline 1200 mg/day or placebo added to regular medications for 6 months. Pentoxifylline has not a significant additive antimicroalbuminuric effect compared with placebo in patients with type 2 diabetes with early stage of kidney disease; further clinical investigations are necessary to be done

Methods

Results

Conclusion